Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate is on track for a potential approval for CTx-1301 and CTx-1302 in mid-2026, and a subsequent commercialization in early 2027. With a large market potential for its products in the ADHD and anxiety treatment spaces, and a discounted cash flow-based valuation of $320M translating to a 12-month price objective of $20 per share, Cingulate's current valuation presents a very attractive opportunity for investors. While there are risks associated with securing regulatory approval and potential partnership uncertainties, the potential for significant upside outweighs these risks, making Cingulate a strong buy.

Bears say

Cingulate is facing leadership instability as the CEO has been placed on administrative leave for personal issues, and along with ongoing issues, the company has been unable to efficiently work with the FDA to address manufacturing and controls concerns for its lead asset, CTx-1301. Despite the drug's potential as a once-daily, multi-core tablet formulation, the delayed regulatory filing approval decision and continued instability raises concerns for the company's ability to successfully bring CTx-1301 to market, leading to a negative outlook.

Cingulate (CING) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.